Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18309352 | 0.90 | EPHX2 (0.37) | ALDH1A1SMN1; SMN2TSHRMAPK1EPHX2 | |
| SCHEMBL20441245 | 0.85 | CNR2 (0.32) | MEN1KMT2APOLBCNR2HDAC3 | |
| SCHEMBL13300995 | 0.77 | CYP3A4 (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL11799713 | 0.75 | POLB (0.38) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL13684410 | 0.73 | EPHX2 (0.35) | ALDH1A1SMN1; SMN2TSHREPHX2LMNA | |
| SCHEMBL22751829 | 0.72 | CNR2 (0.33) | ALDH1A1CNR2MAPTHDAC3HDAC1 | |
| SCHEMBL10119863 | 0.72 | POLB (0.42) | ALDH1A1SMN1; SMN2EPHX2LMNAKMT2A | |
| SCHEMBL11568932 | 0.72 | MEN1 (0.38) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL5260246 | 0.72 | HTT (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL11955648 | 0.72 | HTT (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215729-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9969711-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969711-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170029403-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029403-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9469629-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140296196-A1 | NK1 ANTAGONISTS | OPKO HEALTH, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8754216-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120295879-A1 | NK1 Antagonists | OPKO HEALTH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8207170-B2 | Heterocyclic substituted piperazines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20080292589-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7417045-B2 | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2008-08-26 | — | — | US | disclosed |
| US-7354922-B2 | Bridged ring NK1 antagonists | SCHERING CORPORATION (US) | 2008-04-08 | — | — | US | disclosed |
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | CXCR3, CXCL10, CXCR1 | ALDH1A1 996/4885SMN1; SMN2 2500/4885TSHR 1661/4885 |
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | ALDH1A1 1721/4885SMN1; SMN2 3427/4885TSHR 1005/4885 |
| US-20140296196-A1 | NK1 ANTAGONISTS | NPSR1, GRPR, PROKR1 | ALDH1A1 1238/4885SMN1; SMN2 4051/4885TSHR 318/4885 |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CXCR1, CCR5 | ALDH1A1 553/4885SMN1; SMN2 3041/4885TSHR 949/4885 |
| US-20080292589-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CCR1 | ALDH1A1 1940/4885SMN1; SMN2 3182/4885TSHR 1000/4885 |
| US-20170029403-A1 | NK 1 ANTAGONISTS | BDKRB1, PROKR1, NPSR1 | ALDH1A1 825/4885SMN1; SMN2 3350/4885TSHR 494/4885 |
| US-20120295879-A1 | NK1 Antagonists | NPSR1, GRPR, PROKR1 | ALDH1A1 1238/4885SMN1; SMN2 4051/4885TSHR 318/4885 |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CCR1, CCR5 | ALDH1A1 648/4885SMN1; SMN2 2744/4885TSHR 1043/4885 |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | ALDH1A1 2229/4885SMN1; SMN2 3386/4885TSHR 967/4885 |
| US-20180215729-A1 | NK 1 ANTAGONISTS | BDKRB1, PROKR1, NPSR1 | ALDH1A1 825/4885SMN1; SMN2 3350/4885TSHR 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.